new glp-1 drug Drugs from the Gray Market Weight loss drugs don't work

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study

Study outcomes included the number needed to treat (NNT) to prevent one case of clinical events, healthcare costs, and cost per case of event prevented

Gastrointestinal symptoms: nausea (20%), diarrhea (15%), vomiting (11%), constipation (6%), dyspepsia (6%), abdominal pain (5%), eructation (4%), gastroesophageal reflux disease (3%), abdominal distension (2%) and flatulence (2%)

Therefore, the aim of the present study is to combine all available data on the safety of these medication classes during pregnancy and lactation

CVOT, cardiovascular outcomes trial